Significance of matrix metalloproteinases and their ihhibitors in normal subjects, solid and blood cancer patients


Cite item

Full Text

Abstract

Matrix metalloproteinases and their inhibitors play an essential role in invasion and dissemination of malignant tumors. The study of expression of MMP and their inhibitors in solid and blood cancer may appear a key study giving assessment of antitumor response.

References

  1. Davidson B., Reich R., Risberg B. et al. The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Ark. Patol. 2002; 3: 47-53.
  2. Nagase H., Woessner J. F. Mattrix metalloproteinase. J. Biol. Chem. 1999; 274: 21491-21494.
  3. Завалишина Л. Э. Молекулярно-биологические факторы инвазивного роста и метастазирования рака при морфологическом исследовании: Дис. ... д-ра биол. наук. М.; 2007.
  4. Zhang B., Wu K. F., Cao Z. Y. et al. IL-18 increases invasiveness of HL-60 myeloid leukemia cells: upregulation of matrix metalloproteinases-9 (MMP-9) expression. Leukemia Res. 2004; 28 (1): 91-95.
  5. Ries C., Pitsch T., Mentele R. et al. Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (auto-)catalytic activation and resistance to inhibition by TIMP-1. Biochem. J. 2007; 405 (3): 547-558.
  6. Marquez-Curtis L. A., Dobrowsky J., Montano J. et al. Matrix metalloproteinase and tissue inhibitor of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br. J. Haematol. 2001; 115 (3): 595-604.
  7. Janowska-Wieczorek A., Marquez L. A., Matsuzaki A. et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br. J. Haematol. 1999; 105: 402-411.
  8. Hayashibara T., Yamada Y., Onimaru Y. et al. Matrix metalloproteinase-9 and vascular endothelial growth factor: a possible link in adult T-cell leukaemia cell invasion. Br. J. Haematol. 2002; 116 (1): 94-102.
  9. Yang L., Dong Z. R., Wen S. P. et al. Relationship between VEGF and MMP-2, MMP-9 in 82 patients with acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006; 14 (1): 15-20.
  10. De Bont E. S. J. M., Rosati S., Jacobs S. et al. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br. J. Haematol. 2001; 113: 296-304.
  11. Nyormoi O., Mills L., Bar-Eli M. An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ. 2003; 10 (5): 558-569.
  12. Ries C., Kolb H., Petrides P. E. Regulation of 92-kD gelatinase release in HL-60 leukemia cells: tumor necrosis factor-alpha as an autocrine stimulus for basal- and phorbol esterinduced secretion. Blood 1994; 83 (12): 3638-3646.
  13. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinase: evolution, structure and function. Biochim. Biophys. Acta 2000; 1477: 267-283.
  14. Klein G., Vellenga E., Fraaje M. W. et al. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e. g. acute leukaemia. Crit. Rev. Oncol. Hematol. 2004; 50: 87-100.
  15. Narla R. K., Dong Y., Klis D. et al. Bis(4,7-dimethyl-1,10-phenanthroline)sulfatooxovanadium(I. V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity. Clin. Cancer Res. 2001; 7 (4): 1094-1101.
  16. Li S., Chen Z. X., Wang W. et al. The expression and clinical implication of gelatinase A leukemic cells. Zhonghua Nei Ke Za Zhi 2003; 42 (10): 684-687.
  17. Schnaper H. W., Grant D. S., Stetler-Stevenson W. G. et al. Type IV collagenase (s) and TIMPs modulate endothelial cell morphogenesis in vitro. J. Cell Physiol. 1993; 156 (2): 235-246.
  18. Ries C., Loher F., Zang C. et al. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin. Cancer Res. 1999; 5 (5): 1115-1124.
  19. Zucker S., Hymowitz M., Conner C. et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues: clinical and experimental applications. Ann. N. Y. Acad. Sci 1999; 878 (1): 212-227.
  20. Triebel S., Blaser J., Gote T. et al. Evidence for the tissue inhibitor of metalloproteinases-1 (TIMP-1) in human polymorphonuclear leukocytes. Eur. J. Biochem. 1995; 231 (3): 714-719.
  21. Travaglino E., Benatti C., Malcovati L. et al. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur. J. Haematol. 2008; 80: 216-226.
  22. Janowska-Wieczorek A., Matsuzaki A., Marquez A. The hematopoietic microenvironment: Matrix metalloproteinases in the hematopoietic Microenvironment. Hematology 2000; 4 (6): 515-527.
  23. Rao Q., Geng Y. Q., An L. L. et al. Expression of gelatinase A and B in cord blood CD34+ cells and leukemic cell lines. Zhonghua Xue Ye Xue Za Zhi 2003; 24 (2): 78-81.
  24. Kuittinen O., Soini Y., Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin lymphoma. Eur. J. Haematol. 2002; 69 (4): 205.
  25. Kuittinen O., Savolainen E. R., Koistinen P. et al. Gelatinase A and B (MMP-2, MMP-9) in leukemia. MMP-2 may indicate a good prognosis in AML. Anticancer Res. 1999; 19: 4395-4400.
  26. Kuittinen O., Savolainen E. R., Koistinen P. et al. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leukemia Res. 2001; 25: 125-131.
  27. Li Lin, Lin D. T., Chang C. J. et al. Marrow matrix metalloproteinase (MMPs) and tissue inhibitor of MMP in acute leukaemia: potential role of MMP-9 as surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br. J. Haematol. 2002; 117 (4): 835-841.
  28. Aref S., Osman E., Mansy S. et al. Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients. Hematol. Oncol. 2007; 25 (3): 121-126.
  29. Suminoe A., Matsuzaki A., Hattori H. et al. Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leukemia Res. 2007; 31 (10): 1437- 1440.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies